Dr. Reddy'S Laboratories (RDY) earnings history
Most recent quarter
- Fiscal period
- Q1 2027
- Period end
- Jun 30, 2026
- EPS actual
- $0.06
- EPS estimate
- $0.09
- EPS surprise
- −39.87%
- Revenue surprise
- −1.75%
- Revenue
- $835.7M
- Revenue estimate
- $850.6M
- Reported
- Jul 22, 2026
Dr. Reddy's Laboratories reported fiscal Q1 2027 results on July 22, 2026. Earnings per share were $0.06, missing the $0.09 estimate by 39.87%. Revenue was $835.7 million, below the $850.6 million consensus. Compared with fiscal Q1 2026, EPS fell 70% from $0.20 and revenue fell about 15.5% from $988.9 million.
The previous quarter was also weak. In fiscal Q4 2026, EPS of $0.07 missed by 31.15% and revenue of $787.5 million came in well under the $869.9 million estimate. Annual EPS was $0.66 in fiscal 2023, $0.81 in 2024 and $0.80 in 2025, then dropped to $0.63 in fiscal 2026. Revenue peaked in fiscal 2025 at about $3.83 billion and eased to $3.73 billion in 2026. The latest quarter's EPS is the lowest in the table, and the high was $0.22 in fiscal Q4 2025. Dr. Reddy's beat estimates 13 times in 20 quarters, but only twice in the last eight.
Fiscal Q2 results came out between October 24 and November 5 in each of the past five years, most recently on October 24, 2025. That points to late October or early November 2026 for the next report, which will show whether earnings recover from the two recent lows.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q1 2027 | Jul 22, 2026 | $0.09 | $0.06 | −39.87% | $835.7M | SEC |
| Q4 2026 | May 12, 2026 | $0.11 | $0.07 | −31.15% | $787.5M | SEC |
| Q3 2026 | Jan 21, 2026 | $0.16 | $0.16 | −2.40% | $951.6M | SEC |
| Q2 2026 | Oct 24, 2025 | $0.19 | $0.20 | +1.92% | $1.0B | SEC |
| Q1 2026 | Jul 23, 2025 | $0.21 | $0.20 | −8.12% | $988.9M | SEC |
| Q4 2025 | May 9, 2025 | $0.21 | $0.22 | +5.82% | $996.2M | SEC |
| Q3 2025 | Jan 23, 2025 | $0.21 | $0.20 | −5.98% | $969.6M | SEC |
| Q2 2025 | Nov 5, 2024 | $0.21 | $0.18 | −13.57% | $951.1M | SEC |
| Q1 2025 | Jul 29, 2024 | $0.19 | $0.20 | +3.64% | $916.3M | SEC |
| Q4 2024 | May 7, 2024 | $0.18 | $0.19 | +6.35% | $848.1M | SEC |
| Q3 2024 | Jan 30, 2024 | $0.18 | $0.20 | +12.68% | $868.0M | SEC |
| Q2 2024 | Oct 27, 2023 | $0.17 | $0.21 | +22.16% | $826.4M | SEC |
| Q1 2024 | Jul 26, 2023 | $0.15 | $0.21 | +33.51% | $822.4M | SEC |
| Q4 2023 | May 10, 2023 | $0.12 | $0.14 | +21.98% | $767.0M | SEC |
| Q3 2023 | Jan 25, 2023 | $0.14 | $0.18 | +35.07% | $829.8M | SEC |
| Q2 2023 | Oct 28, 2022 | $0.11 | $0.16 | +43.67% | $764.6M | — |
| Q1 2023 | Jul 28, 2022 | $0.10 | $0.18 | +75.15% | $653.9M | — |
| Q4 2022 | May 19, 2022 | $0.10 | $0.13 | +27.38% | $699.4M | — |
| Q3 2022 | Jan 28, 2022 | $0.13 | $0.11 | −11.15% | $708.9M | — |
| Q2 2022 | Oct 29, 2021 | $0.11 | $0.16 | +41.73% | $769.7M | — |
Quarterly revenue
Frequently asked questions
When did Dr. Reddy'S Laboratories (RDY) last report earnings?
Dr. Reddy'S Laboratories last reported on Jul 22, 2026, covering fiscal Q1 2027.
Did RDY beat earnings estimates?
No. Dr. Reddy'S Laboratories reported EPS of $0.06 for Q1 2027 against a $0.09 estimate — a 39.87% miss.
How much revenue did RDY report last quarter?
Dr. Reddy'S Laboratories reported $835.7M in revenue for Q1 2027, against a consensus estimate of $850.6M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.